The Network aims to promote multi-disciplinary approaches to address challenging vaccine-related questions. This page contains a curated list of publications that highlight high-impact and collaborative approaches.


BibTex format

author = {White, MT and Verity, R and Griffin, JT and Asante, KP and Owusu-Agyei, S and Greenwood, B and Drakeley, C and Gesase, S and Lusingu, J and Ansong, D and Adjei, S and Agbenyega, T and Ogutu, B and Otieno, L and Otieno, W and Agnandji, ST and Lell, B and Kremsner, P and Hoffman, I and Martinson, F and Kamthunzu, P and Tinto, H and Valea, I and Sorgho, H and Oneko, M and Otieno, K and Hamel, MJ and Salim, N and Mtoro, A and Abdulla, S and Aide, P and Sacarlal, J and Aponte, JJ and Njuguna, P and Marsh, K and Bejon, P and Riley, EM and Ghani, AC},
doi = {10.1016/S1473-3099(15)00239-X},
journal = {Lancet Infectious Diseases},
pages = {1450--1458},
title = {Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial},
url = {},
volume = {15},
year = {2015}

RIS format (EndNote, RefMan)

AB - BackgroundThe RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, inducing antibodies associated with the prevention of Plasmodium falciparum infection. We assessed the association between anti-circumsporozoite antibody titres and the magnitude and duration of vaccine efficacy using data from a phase 3 trial done between 2009 and 2014.MethodsUsing data from 8922 African children aged 5–17 months and 6537 African infants aged 6–12 weeks at first vaccination, we analysed the determinants of immunogenicity after RTS,S/AS01 vaccination with or without a booster dose. We assessed the association between the incidence of clinical malaria and anti-circumsporozoite antibody titres using a model of anti-circumsporozoite antibody dynamics and the natural acquisition of protective immunity over time.FindingsRTS,S/AS01-induced anti-circumsporozoite antibody titres were greater in children aged 5–17 months than in those aged 6–12 weeks. Pre-vaccination anti-circumsporozoite titres were associated with lower immunogenicity in children aged 6–12 weeks and higher immunogenicity in those aged 5–17 months. The immunogenicity of the booster dose was strongly associated with immunogenicity after primary vaccination. Anti-circumsporozoite titres wane according to a biphasic exponential distribution. In participants aged 5–17 months, the half-life of the short-lived component of the antibody response was 45 days (95% credible interval 42–48) and that of the long-lived component was 591 days (557–632). After primary vaccination 12% (11–13) of the response was estimated to be long-lived, rising to 30% (28–32%) after a booster dose. An anti-circumsporozoite antibody titre of 121 EU/mL (98–153) was estimated to prevent 50% of infections. Waning anti-circumsporozoite antibody titres predict the duration of efficacy against clinical malaria across different age categories and transmission intensities, and effi
AU - White,MT
AU - Verity,R
AU - Griffin,JT
AU - Asante,KP
AU - Owusu-Agyei,S
AU - Greenwood,B
AU - Drakeley,C
AU - Gesase,S
AU - Lusingu,J
AU - Ansong,D
AU - Adjei,S
AU - Agbenyega,T
AU - Ogutu,B
AU - Otieno,L
AU - Otieno,W
AU - Agnandji,ST
AU - Lell,B
AU - Kremsner,P
AU - Hoffman,I
AU - Martinson,F
AU - Kamthunzu,P
AU - Tinto,H
AU - Valea,I
AU - Sorgho,H
AU - Oneko,M
AU - Otieno,K
AU - Hamel,MJ
AU - Salim,N
AU - Mtoro,A
AU - Abdulla,S
AU - Aide,P
AU - Sacarlal,J
AU - Aponte,JJ
AU - Njuguna,P
AU - Marsh,K
AU - Bejon,P
AU - Riley,EM
AU - Ghani,AC
DO - 10.1016/S1473-3099(15)00239-X
EP - 1458
PY - 2015///
SN - 1473-3099
SP - 1450
TI - Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial
T2 - Lancet Infectious Diseases
UR -
UR -
VL - 15
ER -